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BACKGROUND The Vessix Renal Denervation System (Boston Scien-
tiﬁc, Marlborough, MA) consists of an over-the-wire low-pressure
balloon catheter with an array of bipolar radiofrequency electrodes.
Primary endpoint results of the REDUCE-HTN trial showed signiﬁcant
blood pressure reductions and a low major adverse event rate 6
months following treatment with the Vessix system. Ofﬁce blood
pressure measurements and safety monitoring continues through 2
years post-treatment.
METHODS The REDUCE-HTN trial is a prospective, multicenter, sin-
gle-arm study. Patients were required to have an ofﬁce-based systolic
blood pressure 160 mmHg despite treatment with 3 antihyperten-
sive medications at maximally tolerated doses.
RESULTS Among enrolled patients (N¼146), mean baseline ofﬁce blood
pressurewas 182.418.4/100.114.0mmHgandambulatory bloodpressure
was 152.915.2/87.513.3 mmHg. Among 94 patients with 18 month data,
mean ofﬁce blood pressure was reduced to 157.224.6/86.914.8mmHg; a
reduction of 27.120.4/11.211.4 mmHg (P<.0001). Eighty percent of those
(75/94) responded to treatment with a reduction in ofﬁce systolic blood
pressure 10 mmHg at 18 months. The rate of procedure-related serious
adverse events was 5.6% at 6 months, with no new procedure- or device-
related serious adverse events reported between6 and 18months of follow-
up. Final 2-year efﬁcacy and safety data will be available at the time of
presentation.
CONCLUSIONS Eighteen-month data available to date from the
REDUCE-HTN study support the safety and efﬁcacy of renal dener-
vation with the Vessix system to treat resistant hypertension, with
potential for sustained blood pressure reductions through 2 years.
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BACKGROUND Renal sympathetic denervation (RDN) has been
introduced as a possible treatment for resistant hypertension (RH);
however, the largest trial to date has shown little beneﬁt. Our aim was
to compare renal denervation versus pharmacological therapy in pa-
tients with resistant hypertension in eight trials.
METHODS We conducted a meta-analysis of prospective trials which
randomized patients with resistant hypertension to renal denervation
or pharmacological antihypertensive treatment alone and reported
the pre-speciﬁed outcomes. Mantel Haenszel relative risks and mean
differences were calculated using random effect models.
RESULTS Eight trials (N¼1011)met the inclusion criteria. At 6months RDN
was associated with greater reduction in 24-hour systolic blood pressure(SBP) (mean difference -3.21; 95% CI -5.19, -1.24; P¼0.001), and 24-hour
diastolic blood pressure (DBP) (mean difference -1.60; 95% CI -2.76, -0.44;
P¼0.007). RDN was also associated with a decrease in the number of anti-
hypertensive medications compared to the control arm (mean difference
-0.32; 95%CI -0.52, -0.11; P¼0.002).Themeandifference inchangebetween
RDNand controlwas -7.69mmHg for ofﬁce SBP (P¼0.18), and -4.54mmHg
for DBP (P¼0.009) favoring RDN. Sensitivity analysis including trials with
homogenous antihypertensivemedical treatment protocol among the RDN
andcontrols showedsigniﬁcant reductions inofﬁce systolic anddiastolicBP
at 6 months favoring RDN (mean difference -14.6; 95% CI -26.28, -2.92;
P¼0.01), (meandifference -6.06;95%CI -9.60, -2.53; P<0.001), respectively.
There was no signiﬁcant difference in terms of heart rate, kidney function,
myocardial infraction, stroke, or hypertensive emergency.CONCLUSIONS RDN is associated with signiﬁcant 24-hour ambula-
tory and ofﬁce based reduction in both systolic and diastolic blood
pressure compared to pharmacological treatment alone. Renal
denervation is safe and may have a potential role as an adjunct
treatment in patients with resistant hypertension.
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BACKGROUND Transcatheter renal denervation (RDN) therapy has
emerged as a therapeutic option for patients diagnosed hypertension
resistant to pharmacologic therapy. We aimed to evaluate the effects
of radiofrequency treatment (RF) delivered by the Terumo Iberis
catheter in a large animal model. Additionally, as a secondary end
point, we aimed to determine the safety implications of delivery of
one cycle versus two cycles of RF ablations.
METHODS 22 domestic swine were enrolled. 18 animals underwent RDN,
performed bilaterally; 4 remained untreated as naïve controls for norepi-
nephrine levels (NE) only. Renal arteries were randomized to receive a
single cycleof 120seconds (n¼24) treatment andwere followed for7, 30and
90 days. 8 renal arteries received 2 treatment cycles (240 seconds total) and
were followed for 7 days only. 3 arteries were untreated. Renal cortical
samples from the single-cycle treatment group were harvested for NE
evaluation at each timepoint.All renal arterieswereharvested forhistology
and immunohistochemical (IHC) evaluation.
RESULTS All renal arterieswere suitable forRF therapybyangiography.The
characteristic “notches” post-RF were observed in all treated arteries. At
follow up, all arteries demonstrated no luminal obstruction with a TIMI 3
ﬂow.TheNEassay showeda 70%decrease inNE levels (76.6857.87 ng/g) at
7 days post RDN, 81% signiﬁcant decrease at 30 days (49.0545.81 ng/g), and
51%decrease at 90 days (12.773.2 ng/g) compared to control (254.154.1 ng/
g). Histologically, the thermal effect in the perivascular tissue extended from
an average of 40% to a complete (100%) circumferential involvement with a
depthreachingupto8mm.TheprimaryhistologicalandIHCfeatureat 7days
was nerve necrosis with consequent nerve atrophy distal to the RF treated
level; the arterial wall showed complete re-endothelialization and hyalini-
zation of the media (thermal coagulation necrosis). At 30 days, necrosis was
no longer prominent and was replaced by healing changes of ﬁbrosis. Neu-
romatous regenerationwas apparent at 30days atRF treated levels, a change
characterized by disorganized sprouting of neuroid ﬁbers within the thick-
ened perineurium. At 90 days these features progressed to become more
